Compare Heron Therapeutics Inc (HRTX) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Uber Technologies Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Uber Technologies Inc trades at $78.38 (market cap $159.38B). The key difference: Uber Technologies Inc is far larger — about 2513.5× Heron Therapeutics Inc's market cap, and Uber Technologies Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | UBER | |
|---|---|---|
Market Cap | $63.41M | $159.38B |
Sector | Health | Industrials |
52-Week High | $1.49 | $100.10 |
52-Week Low | $0.33 | $65.94 |
Enterprise Value | $161.31M | $168.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Uber Technologies (UBER) is trading at $75.02, up 6.46% today, with strong technical momentum and bullish moving averages. The company shows robust revenue growth from $31.9B in 2022 to $52.0B in 2025, with net income turning positive since 2023. Recent developments include expansion into autonomous vehicle partnerships and strategic workforce adjustments in HR roles.
Uber presents a compelling growth story with improving profitability and strong analyst support (81.67% buy rating). Key risks include execution challenges in autonomous vehicle deployment and competitive pressures in key markets like India. The consensus price target of $102.88 suggests significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
